bronchiectasi
complex
chronic
respiratori
condit
tradit
character
recurr
infect
airway
inflamm
progress
declin
lung
function
defin
symptom
common
children
bronchiectasi
chronic
wet
cough
regionspecif
studi
suggest
geograph
local
socioeconom
environ
play
larg
role
determin
like
etiolog
bronchiectasi
children
cystic
fibrosi
primari
immun
defici
defect
mucociliari
clearanc
mechan
primari
ciliari
dyskinesia
congenit
malform
aspir
foreign
bodi
increas
suscept
respiratori
infect
known
associ
bronchiectasi
children
howev
global
scale
lower
respiratori
infect
absenc
known
underli
condit
account
greatest
number
bronchiectasi
case
focu
review
bronchiectasi
known
underli
disord
children
underprivileg
popul
includ
popul
within
affluent
societi
indigen
popul
australia
new
zealand
alaska
sever
lower
respiratori
infect
earli
life
like
caus
bronchiectasi
global
estim
sever
bacteri
viral
pneumonia
account
approxim
case
postinfect
pediatr
bronchiectasi
measl
tuberculosi
combin
account
although
pneumonia
signific
risk
factor
bronchiectasi
proport
children
develop
bronchiectasi
follow
episod
pneumonia
mechan
involv
progress
acut
lower
respiratori
infect
chronic
inflamm
persist
infect
poorli
understood
earli
diagnosi
intens
treatment
protocol
stabil
even
improv
clinic
prognosi
children
bronchiectasi
decad
consider
advanc
made
identifi
pathogen
associ
recurr
chronic
infect
howev
understand
host
immunolog
mechan
contribut
recurr
infect
prolong
inflamm
identifi
import
area
research
would
contribut
substanti
effect
prevent
strategi
children
risk
bronchiectasi
review
begin
explor
role
child
immun
respons
establish
environ
conduc
recurr
infect
chronic
inflamm
characterist
bronchiectasi
follow
discuss
import
pathogen
associ
bronchiectasi
children
obstacl
treat
prevent
infect
review
conclud
road
forward
area
research
identifi
author
import
advanc
understand
address
pathogenesi
bronchiectasi
children
recent
year
consider
effort
made
understand
airway
inflamm
associ
bronchiectasi
parallel
exist
bronchiectasi
chronic
respiratori
disord
includ
cystic
fibrosi
chronic
obstruct
pulmonari
diseas
copd
relat
airway
inflamm
result
inflammatori
process
involv
cystic
fibrosi
copd
sometim
use
attempt
understand
pathophysiolog
bronchiectasi
howev
cystic
fibrosi
copd
distinctli
differ
etiolog
bronchiectasi
children
extrapol
data
particularli
pediatr
set
done
caution
nevertheless
similar
chronic
respiratori
condit
suggest
bronchiectasi
aris
exagger
andor
dysregul
inflamm
respons
challeng
respiratori
pathogen
thu
viciou
circl
hypothesi
selfperpetu
infect
inflamm
tissu
damag
first
describ
cole
remain
like
explan
pathogenesi
bronchiectasi
remain
question
caus
highli
control
immun
respons
becom
dysregul
innat
inflammatori
respons
one
rapid
respons
unit
immun
system
pathogen
penetr
physiolog
barrier
epithelium
seri
highli
regul
cellular
noncellular
event
coordin
rapidli
contain
infect
addit
role
first
respons
unit
inflammatori
respons
also
orchestr
initi
pathogenspecif
adapt
respons
function
optim
initi
inflammatori
process
resolv
rapidli
begin
maintain
tissu
homeostasi
dysfunct
whether
exagger
initi
respons
delay
resolut
may
caus
accumul
potent
cytotox
compound
damag
host
tissu
provid
environ
conduc
infect
difficulti
associ
obtain
lower
airway
specimen
young
children
preclud
comprehens
studi
local
inflammatori
mechan
contribut
bronchiectasi
result
much
current
knowledg
airway
inflamm
children
bronchiectasi
deriv
small
crosssect
studi
retrospect
chart
review
extrapol
data
studi
bronchiectasi
adult
despit
limit
studi
bronchiectasi
children
variou
environ
consist
show
neutrophil
inflamm
airway
well
elev
level
associ
proinflammatori
cytokin
antimicrobi
compound
consist
inflammatori
respons
bacteri
assault
howev
addit
neutrophil
inflamm
eosinophil
inflamm
describ
young
australian
indigen
children
newli
diagnos
bronchiectasi
suggest
complex
inflammatori
pathway
may
contribut
bronchiectasi
neutrophil
airway
inflamm
also
characterist
bronchiectasi
adult
neutrophil
count
inflammatori
cytokin
includ
elev
period
infect
exacerb
key
marker
inflamm
continu
persist
period
appar
clinic
stabil
increas
level
inflammatori
marker
lung
associ
sever
respiratori
symptom
includ
poorer
lung
function
correl
posit
anatom
extent
bronchiectasi
pediatr
studi
import
understand
pathogenesi
bronchiectasi
inflamm
absenc
bacteri
infect
children
rel
newli
recogn
diseas
could
mean
neutrophil
inflamm
indic
abnorm
immun
regul
rather
symptom
chronic
infect
although
tradit
recogn
inflammatori
diseas
airway
grow
bodi
evid
bronchiectasi
may
also
includ
system
inflammatori
compon
studi
children
found
limit
indic
system
inflamm
use
standard
clinic
marker
inflamm
creactiv
protein
crp
total
white
cell
count
protein
platelet
studi
children
found
children
bronchiectasi
clinic
stabl
higher
proport
circul
proinflammatori
lymphocyt
produc
perforin
granzym
compar
children
without
suppur
lung
condit
studi
small
crosssect
design
howev
rais
possibl
lowgrad
level
system
inflamm
present
children
bronchiectasi
current
detect
standard
investig
system
inflamm
rel
common
adult
bronchiectasi
elev
level
circul
inflammatori
cell
neutrophil
total
white
cell
count
well
solubl
serum
mediat
includ
transform
growth
factor
tgf
crp
fibrinogen
solubl
adhes
molecul
describ
adult
longstand
diseas
high
level
system
inflamm
associ
acceler
declin
lung
function
therefor
novel
marker
monitor
lowgrad
system
inflamm
may
import
manag
prevent
progress
diseas
children
neutrophil
inflamm
airway
often
present
bronchiectasi
presenc
appar
absenc
bacteri
infect
healthi
lung
neutrophil
one
key
cell
involv
drive
inflammatori
respons
invad
pathogen
neutrophil
recruit
peripher
circul
local
popul
macrophag
neutrophil
circul
neutrophil
rapidli
migrat
airway
respons
proinflammatori
mediat
includ
primari
role
neutrophil
elimin
invad
pathogen
first
phagocytosi
follow
releas
arsen
antimicrobi
product
within
phagosom
significantli
stimul
neutrophil
degranul
deploy
potent
proteas
includ
neutrophil
elastas
cathepsin
myeloperoxidas
inadvert
releas
proteas
also
degrad
matrix
protein
host
airway
wall
promot
inflamm
healthi
lung
process
tightli
regul
prevent
excess
damag
host
tissu
impair
function
andor
dysregul
neutrophil
propos
import
pathogenesi
bronchiectasi
current
data
regard
neutrophil
function
children
howev
impair
neutrophil
function
describ
adult
bronchiectasi
associ
sever
diseas
king
colleagu
demonstr
high
preval
impair
bacterialspecif
oxid
burst
function
circul
neutrophil
larg
group
adult
bronchiectasi
furthermor
patient
low
capac
neutrophilgener
oxid
burst
also
demonstr
reduc
capac
intracellular
bactericid
activ
neutrophil
data
howev
reflect
two
small
studi
adult
bronchiectasi
impair
oxid
burst
circul
neutrophil
found
although
impair
airway
neutrophil
observ
discrep
data
may
attribut
method
use
induc
oxid
burst
bacteri
phagocytosi
versu
synthet
peptid
clinic
characterist
studi
cohort
age
sever
diseas
studi
king
colleagu
phagocytosi
intracellular
kill
investig
use
bacteri
challeng
may
repres
altern
accur
pathway
activ
compar
use
peptid
challeng
despit
conflict
data
studi
found
evid
impair
microbicid
activ
albeit
differ
popul
neutrophil
suggest
function
phagocytosi
accompani
impair
intracellular
kill
may
one
strategi
employ
pathogen
establish
intracellular
nich
avoid
host
clearanc
mechan
possibl
impair
phagocytosi
intracellular
kill
mechan
correl
diseas
sever
highlight
need
investig
role
neutrophil
function
progress
bronchiectasi
children
earli
stage
chronic
diseas
eosinophil
compris
small
potent
proport
leukocyt
popul
circul
lung
recruit
activ
eosinophil
associ
sever
respiratori
disord
includ
asthma
eosinophil
bronchiti
well
parasit
infect
although
rare
report
associ
bronchiectasi
studi
identifi
high
preval
airway
eosinophilia
australian
indigen
children
bronchiectasi
correl
circul
eosinophil
limit
investig
implic
possibl
role
virus
elev
airway
eosinophil
howev
like
airway
eosinophilia
children
bronchiectasi
multipl
etiolog
includ
parasit
infect
coexist
asthma
hypersensit
fungi
adult
chronic
airway
diseas
includ
bronchiectasi
eosinophilia
thought
associ
sever
diseas
therefor
import
understand
etiolog
airway
eosinophilia
contribut
perpetu
chronic
inflamm
pathogenesi
bronchiectasi
macrophag
phagocyt
cell
multipl
phenotyp
abund
cell
uninflam
lung
typic
compris
cellular
profil
bronchoalveolar
lavag
bal
fluid
resid
around
interstiti
tissu
interstiti
macrophag
within
surfact
fluid
line
alveoli
alveolar
macrophag
hodg
colleagu
recent
show
first
time
alveolar
macrophag
dysfunct
children
bronchiectasi
compar
control
children
alveolar
macrophag
children
bronchiectasi
reduc
capac
efferocytosi
bronchial
epitheli
cell
phagocytosi
nontyp
haemophilu
influenza
nthi
impair
efferocytosi
apoptot
epitheli
cell
neutrophil
also
describ
adult
asthma
copd
effici
efferocytosi
paramount
prevent
secondari
necrosi
releas
toxic
factor
lung
microenviron
impair
abil
clear
apoptot
host
cell
pathogen
would
like
contribut
environ
conduc
tissu
damag
persist
infect
pathogenesi
bronchiectasi
bacteri
infect
play
import
role
pathogenesi
bronchiectasi
children
sever
lower
respiratori
infect
infanc
signific
risk
factor
bronchiectasi
idiopath
bronchiectasi
adult
often
trace
back
histori
lower
respiratori
infect
childhood
nthi
pathogen
commonli
associ
bronchiectasi
review
grimwood
howev
nthi
also
present
commens
organ
children
without
respiratori
diseas
despit
dual
exist
nthi
commens
organ
import
respiratori
pathogen
littl
known
develop
natur
immun
nthi
remain
undisput
local
physiolog
characterist
bronchiectasi
contribut
environ
support
bronchiectasi
children
immunologymicrobiolog
frontier
pediatr
wwwfrontiersinorg
may
volum
articl
recurr
persist
infect
dilat
airway
excess
mucu
retent
dysfunct
cilia
complementari
studi
children
adult
shown
adapt
immun
respons
particularli
cellmedi
immun
respons
import
factor
contribut
recurr
respiratori
infect
nthi
vitro
challeng
assay
blood
mononuclear
cell
indic
cellmedi
immun
respons
nthi
may
compromis
children
bronchiectasi
demonstr
reduc
capac
produc
respons
nthi
importantli
compromis
cellmedi
immun
respons
strongli
associ
airway
inflamm
specif
elev
level
indic
possibl
link
local
inflamm
system
adapt
immun
mechan
drive
associ
airway
inflamm
nthidriven
children
bronchiectasi
determin
howev
integr
initi
phenotyp
adapt
immun
respons
drive
inflammatori
cascad
local
neutrophil
promot
product
inflammatori
modul
protein
play
complex
role
inflammatori
respons
promot
inflamm
wound
heal
dysregul
pathway
associ
chronic
inflamm
addit
inflammatori
modul
properti
integr
initi
adapt
respons
direct
primari
phenotyp
lung
polar
adapt
immun
respons
favor
humor
respons
inhibit
product
promot
differenti
bcell
antibodyproduc
plasma
cell
data
suggest
may
simpli
marker
inflamm
rather
indic
suboptim
thelper
pathway
result
impair
clearanc
mechan
persist
infect
collect
data
support
associ
impair
cellmedi
immun
respons
nthi
dysregul
airway
inflamm
pathogenesi
bronchiectasi
children
data
children
complement
extens
studi
nthispecif
immun
respons
adult
show
polar
cellmedi
immun
respons
contribut
protect
immun
nthi
studi
king
colleagu
show
circul
thelper
cell
healthi
adult
respond
vitro
nthi
challeng
increas
express
predominantli
classic
manner
contrast
cytokin
respons
adult
bronchiectasi
chronic
nthi
infect
polar
favor
complement
low
express
sever
factor
may
contribut
differ
cytokin
profil
gener
respons
nthi
includ
reduct
size
pool
memori
tcell
howev
king
colleagu
show
polar
cytokin
profil
direct
relat
skew
cytokin
produc
rather
overal
reduct
absolut
number
tcell
addit
tcell
cytotox
tcell
implic
chronic
infect
nthi
tcell
capac
switch
polar
respons
phenotyp
switch
investig
respect
chronic
nthi
infect
howev
tcell
adult
bronchiectasi
demonstr
nonspecif
capac
produc
realiz
respons
specif
challeng
nthi
phenotyp
switch
one
mechan
may
explain
collect
studi
suggest
children
adult
bronchiectasi
like
necessari
cellmedi
immun
architectur
respond
nthi
children
recent
onset
diseas
adult
establish
bronchiectasi
univers
capac
produc
similar
healthi
control
fail
respons
nthi
rais
possibl
use
therapeut
strategi
vaccin
improv
immun
nthi
promot
protect
respons
data
support
strategi
show
children
bronchiectasi
capac
produc
respons
nthi
highest
receiv
three
dose
pneumococc
conjug
vaccin
contain
h
influenza
protein
phidcv
surfac
protein
express
h
influenza
present
hib
vaccin
protein
adjuv
properti
like
contribut
higher
cytokin
respons
phidcvvaccin
children
role
humor
respons
pathogenesi
bronchiectasi
unclear
consider
publish
data
show
chronic
colon
activ
infect
lower
airway
nthi
despit
presenc
activ
humor
immun
respons
adult
chronic
respiratori
condit
includ
bronchiectasi
chronic
bronchiti
copd
also
exhibit
comprehens
humor
immun
respons
nthi
ampl
amount
specif
total
igg
igg
subclass
iga
igm
present
circul
antibodi
function
nthi
vitro
combin
serum
complement
form
potent
nthiclear
mechan
although
amount
circul
immunoglobulin
age
depend
children
also
appear
profici
produc
nthispecif
igg
thought
strong
univers
humor
respons
one
main
reason
nthi
rare
caus
system
infect
howev
high
system
antibodi
level
appear
correl
protect
respiratori
infect
secretori
iga
main
immunoglobulin
associ
mucos
immunolog
data
nthispecif
secretori
iga
lack
small
studi
adult
patient
indic
defici
secretori
iga
associ
bronchiectasi
chronic
bronchiti
contrast
vitro
studi
shown
nthi
produc
human
iga
proteas
may
facilit
intern
persist
surviv
within
lung
epitheli
cell
plausibl
impair
antibodi
function
rather
defici
level
antibodi
may
contribut
recurr
infect
nthi
bronchiectasi
altern
presenc
bacteri
biofilm
host
bronchial
secret
may
imped
activ
antibodi
howev
data
confirm
refut
children
adult
bronchiectasi
collect
data
indic
chronic
infect
nthi
unlik
attribut
overal
defici
antibodi
product
howev
nthi
heterogen
speci
induc
product
strainspecif
antibodi
thu
suggest
antibodi
specif
may
explain
inabl
previou
infect
protect
futur
infect
nthi
contrari
hypothesi
consider
degre
function
antibodi
crossreact
demonstr
differ
nthi
strain
furthermor
children
adult
high
turnov
strain
carriag
multipl
strain
often
carri
concurr
henc
would
expect
high
level
antibodi
divers
circul
one
time
significantli
restrict
number
infect
regardless
strain
specif
data
preclud
role
humor
immun
protect
respiratori
infect
nthi
humor
immun
like
play
signific
role
protect
system
airway
diseas
howev
high
preval
recurr
infect
presenc
high
level
antibodi
support
argument
increas
suscept
infect
nthi
close
link
cellmedi
immun
respons
humor
immun
respons
respiratori
pathogen
employ
varieti
strategi
avoid
clearanc
host
defens
mechan
success
strategi
inhibit
host
effect
clear
infect
contribut
environ
support
chronic
infect
associ
inflamm
primari
strategi
employ
common
respiratori
pathogen
includ
format
protect
structur
biofilm
h
influenza
pseudomona
aeruginosa
staphylococcu
aureu
streptococcu
pneumonia
secret
immuneblock
agent
iga
proteas
h
influenza
secret
toxin
damag
mucusclear
structur
includ
cilia
epithelium
secret
proteas
damag
structur
bronchial
wall
includ
cilia
hamper
sputum
clearanc
lung
promot
inflammatori
process
host
biofilm
report
lower
airway
children
bronchiectasi
imped
action
antibiot
pathogen
associ
chronic
respiratori
infect
includ
h
influenza
mycobacterium
tuberculosi
avoid
host
humor
respons
manipul
host
phagocyt
cell
hijack
antimicrobi
mechan
establish
intracellular
nich
studi
report
bacteria
associ
bronchiectasi
children
list
tabl
h
influenza
specifi
nontyp
nthi
three
studi
common
pathogen
identifi
follow
pneumonia
moraxella
catarrhali
three
speci
commonli
associ
acut
exacerb
adult
bronchiectasi
less
common
combin
result
pediatr
studi
indic
p
aeruginosa
aureu
similar
preval
catarrhali
although
result
difficult
compar
given
differ
specimen
type
use
tabl
preval
h
influenza
pneumonia
catarrhali
bronchiectasi
form
basi
empir
antibiot
therapi
treat
acut
exacerb
children
howev
evid
base
primarili
crosssect
studi
children
clinic
stabl
retrospect
chart
review
evid
role
five
main
bacteria
bronchiectasi
review
follow
section
togeth
data
resist
macrolid
antibiot
commonli
use
treat
respiratori
infect
haemophilu
influenza
gramneg
pleomorph
coccobacillu
noncapsul
nontyp
strain
nthi
common
colon
upper
respiratori
tract
urt
bacterium
commonli
isol
airway
children
adult
bronchiectasi
nthi
like
contribut
substanti
recurr
respiratori
infect
fact
signific
nthi
pediatr
bronchiectasi
note
year
ago
conclus
noncapsul
h
influenza
respons
keep
chronic
inflammatori
process
smolder
bronchiectat
individu
nthi
also
opportunist
pathogen
associ
respiratori
infect
otiti
media
om
sinus
pneumonia
children
number
virul
factor
employ
nthi
provid
environ
conduc
infect
chronic
colon
includ
product
biofilm
secret
proteas
mention
previous
review
biofilm
recent
describ
children
bronchiectasi
recent
evid
vitro
studi
suggest
nthi
may
manipul
activ
neutrophil
facilit
product
biofilm
nthi
also
produc
human
iga
proteas
vitro
contribut
invas
surviv
within
human
respiratori
epitheli
cell
accur
identif
nthi
import
sinc
nonhemolyt
strain
close
relat
primarili
commens
haemophilu
haemolyticu
may
misidentifi
nthi
phenotyp
method
molecular
detect
method
found
nasopharyng
np
isol
healthi
otitispron
children
initi
identifi
nthi
use
phenotyp
method
actual
h
haemolyticu
australian
indigen
children
bronchiectasi
phenotyp
nthi
isol
np
bal
confirm
h
influenza
use
hpd
pcr
wherea
oropharyng
op
isol
presumpt
h
haemolyticu
nthi
lower
airway
infect
also
confirm
use
hpd
pcr
quantit
compar
measur
bacteri
densiti
total
differenti
cell
count
gage
airway
inflammatori
respons
infect
molecular
studi
differenti
nthi
h
haemolyticu
reaffirm
import
nthi
lower
airway
pathogen
pediatr
bronchiectasi
shown
np
rather
op
prefer
site
nthi
carriag
studi
pediatr
popul
resist
ampicillin
antibiot
h
influenza
gener
limit
product
case
neg
ampicillinresist
blnar
strain
presenc
alter
penicillinbind
protein
pbp
overal
preval
posit
respiratori
tract
strain
larg
intern
surveil
studi
protekt
rang
germani
south
korea
strain
blnar
anoth
larg
intern
studi
clinic
h
influenza
strain
found
intrins
macrolid
efflux
mechan
azithromycin
minimum
inhibitori
concentr
mic
mgl
highlevel
macrolid
resist
mic
mgl
due
ribosom
alter
defin
hypersuscept
mic
mgl
crosssect
studi
australian
indigen
children
bronchiectasi
nthi
isol
np
bal
respect
posit
respect
azithromycin
resist
mic
mgl
isol
test
intermedi
azithromycin
resist
streptococcu
pneumonia
pneumococcu
gramposit
diplococcu
second
common
pathogen
associ
bronchiectasi
children
tabl
least
serotyp
identifi
basi
polysaccharid
capsul
capsul
import
virul
factor
shield
organ
host
immun
system
also
import
vaccin
target
pneumococci
colon
nasopharynx
healthi
individu
opportunist
pathogen
caus
acut
local
infect
om
sinus
communityacquir
bacteri
pneumonia
invad
bloodstream
result
mening
sepsi
acut
pneumococc
infect
complic
studi
extens
children
emerg
evid
indic
role
immun
pathway
protect
mucos
infect
pneumonia
howev
littl
known
role
pneumococci
establish
maintain
persist
lower
airway
endobronchi
infect
bronchiectasi
sever
recurr
pneumonia
episod
earli
life
signific
risk
factor
bronchiectasi
plausibl
earli
infect
pneumonia
initi
immunolog
event
contribut
pathogenesi
bronchiectasi
worldwid
preval
pneumococc
pediatr
respiratori
tract
isol
highlevel
penicillin
resist
mic
mgl
estim
conspicu
differ
countri
pneumococc
resist
primarili
mediat
alter
pbp
highli
penicillinresist
strain
pbp
alter
strain
exhibit
intermedi
resist
mic
mgl
macrolid
resist
pneumococc
pediatr
respiratori
tract
isol
worldwid
overal
erythromycin
mic
mgl
exceed
penicillin
resist
countri
survey
macrolid
resist
occur
two
main
mechan
ribosom
methylas
macrolid
efflux
system
azithromycin
report
effect
suscept
strain
pneumonia
howev
relev
mic
breakpoint
controversi
depend
site
infect
treatment
failur
mostli
report
communityacquir
pneumonia
gener
mic
mgl
howev
treatment
failur
report
om
mic
mgl
crosssect
studi
australian
indigen
children
bronchiectasi
pneumonia
isol
np
bal
respect
penicillin
nonsuscept
highlevel
penicillin
resist
detect
respect
azithromycin
resist
azithromycin
mic
mgl
random
control
trial
rct
weekli
azithromycin
versu
placebo
indigen
children
bronchiectasi
year
azithromycin
resist
pneumonia
np
swab
significantli
higher
azithromycin
compar
placebo
group
howev
resist
declin
follow
conclus
intervent
median
month
later
indic
fit
cost
macrolid
resist
pneumonia
similarli
studi
singledos
azithromycin
biannual
mass
treatment
trachoma
shown
increas
rate
pneumococc
macrolid
resist
follow
declin
resist
remov
antibiot
pressur
fit
cost
macrolid
resist
pneumonia
like
ensur
eventu
elimin
replac
resist
strain
suscept
strain
absenc
antibiot
select
moraxella
catarrhali
gramneg
mostli
posit
diplococcu
although
much
research
pediatr
respiratori
condit
focuss
nthi
pneumococcu
catarrhali
overlook
larg
cohort
studi
children
present
cough
catarrhali
pathogen
distinguish
children
without
persist
cough
day
later
catarrhali
also
common
caus
om
infant
children
caus
estim
million
exacerb
copd
adult
annual
usa
catarrhali
strain
produc
protekt
studi
contrast
catarrhali
almost
univers
suscept
azithromycin
although
macrolid
resist
recent
report
china
japan
pakistan
australian
indigen
children
bronchiectasi
catarrhali
isol
np
bal
posit
howev
azithromycin
resist
test
data
locat
macrolid
resist
catarrhali
children
bronchiectasi
given
increas
use
azithromycin
rang
condit
may
prudent
monitor
catarrhali
develop
macrolid
resist
staphylococcu
aureu
gramposit
coccal
bacterium
frequent
found
nose
skin
common
caus
skin
respiratori
infect
commonli
associ
bronchiectasi
adult
although
sometim
found
bal
children
bronchiectasi
tabl
role
pathogenesi
unknown
interest
aureu
intensifi
increas
preval
infect
caus
methicillinresist
aureu
mrsa
mrsa
endem
mani
hospit
throughout
world
highest
rate
north
south
america
southeast
asia
studi
longterm
macrolid
treatment
cystic
fibrosi
patient
bronchiectasi
also
found
high
rate
macrolid
resist
aureu
similarli
found
significantli
higher
macrolid
resist
aureu
np
isol
indigen
children
bronchiectasi
random
longterm
azithromycin
compar
placebo
mrsa
present
less
common
treatment
group
aureu
isol
respect
importantli
aureu
isol
macrolid
resist
follow
conclus
intervent
median
later
provid
first
evid
knowledg
lack
fit
cost
macrolid
resist
pathogen
pseudomona
aeruginosa
gramneg
rodshap
bacterium
opportunist
pathogen
p
aeruginosa
uncommon
young
children
bronchiectasi
found
older
children
adult
bronchiectasi
lower
respiratori
infect
p
aeruginosa
predictor
acceler
lung
function
declin
sever
diseas
mortal
therefor
like
associ
advanc
diseas
numer
mechan
antibiot
resist
attribut
p
aeruginosa
includ
intrins
acquir
multidrug
efflux
pump
data
locat
antibiot
resist
p
aeruginosa
children
bronchiectasi
sinc
lower
airway
infect
result
aspir
pathogen
bacteria
origin
upper
airway
differ
urt
carriag
differ
popul
may
import
four
five
main
bacteria
p
aeruginosa
except
associ
bronchiectasi
common
colon
urt
children
nasal
np
carriag
nthi
pneumonia
catarrhali
common
young
children
particularli
day
care
center
lowincom
countri
howev
high
rate
report
australian
aborigin
children
children
develop
countri
papua
new
guinea
png
gambia
also
high
rate
pneumonia
morbid
mortal
australian
aborigin
gambian
infant
acquir
np
carriag
three
main
respiratori
pathogen
earli
age
urt
burden
higher
indigen
nonindigen
australian
children
nasopharyng
carriag
aureu
high
infant
month
old
declin
rapidli
carriag
three
main
respiratori
bacteria
increas
reach
low
point
year
carriag
increas
reach
highest
preval
children
year
old
np
carriag
figur
extend
viciou
circl
hypothesi
explain
high
rate
chronic
endobronchi
disord
bronchiectasi
high
earli
burden
multipl
pathogen
speci
strain
nasopharynx
indigen
children
children
low
incom
countri
highdos
versu
lowdos
exposur
like
contribut
high
burden
acut
chronic
lower
respiratori
infect
carriag
without
inflamm
usual
clear
may
result
pneumonia
invas
diseas
presenc
virul
strain
andor
underli
diseas
unshad
box
dens
divers
colon
caus
neutrophil
inflamm
mucos
tissu
damag
increas
mucu
secret
decreas
mucociliari
clearanc
lead
chronic
mucos
diseas
recurr
lower
airway
infect
bronchiectasi
shade
box
persist
nasal
discharg
chronic
cough
perpetu
viciou
circl
particularli
poor
hygien
overcrowd
increas
opportun
transmiss
high
rate
transmiss
event
result
accumul
strain
rate
greater
clear
immun
respons
particularli
infant
young
children
damag
mucosa
viciou
circl
bold
arrow
repeat
three
bacteria
declin
aspir
aureu
urt
contribut
bronchiectasi
aureu
lower
airway
infect
may
common
older
children
contrast
p
aeruginosa
consid
part
normal
pharyng
flora
children
cystic
fibrosi
carriag
urt
found
establish
lower
airway
colon
recent
studi
evalu
swab
method
estim
urt
bacteri
carriag
found
low
preval
p
aeruginosa
age
group
aspir
p
aeruginosa
lower
airway
thu
like
rare
event
may
help
explain
pathogen
especi
uncommon
young
children
bronchiectasi
notabl
featur
nthi
carriag
popul
high
carriag
rate
regular
turnov
strain
multipl
np
strain
carri
one
time
popul
high
pneumonia
carriag
australian
aborigin
gambian
png
children
also
high
rate
simultan
multipl
serotyp
carriag
higher
report
popul
pneumococc
serotyp
also
regularli
replac
mean
durat
pneumonia
carriag
kenyan
children
day
rang
day
serotyp
high
level
concord
bacteri
strain
nthi
ribotyp
pneumococc
serotyp
nasopharynx
lung
australian
indigen
children
bronchiectasi
concurr
carriag
lower
airway
infect
suggest
recent
aspir
np
secret
given
high
turnov
np
strain
howev
multipl
strain
nthi
pneumonia
consist
found
frequent
bal
compar
np
specimen
suggest
accumul
strain
lower
airway
result
recurr
aspir
failur
elimin
prior
strain
multipl
nthi
strain
also
report
sputum
microbiolog
adult
chronic
respiratori
condit
probabl
high
earli
burden
pathogen
nasopharynx
indigen
children
children
low
incom
countri
contribut
high
burden
acut
chronic
lower
respiratori
infect
figur
adapt
cole
origin
model
modifi
explain
chronic
lung
diseas
illustr
extend
viciou
circl
hypothesi
explain
high
rate
chronic
endobronchi
disord
bronchiectasi
despit
learn
microbiolog
lower
airway
children
bronchiectasi
challeng
associ
identifi
pathogen
respons
respiratori
exacerb
spontan
induc
sputum
reliabl
access
sourc
specimen
routin
use
microbiolog
analysi
adult
howev
collect
sputum
young
children
problemat
find
difficult
expector
although
np
swab
may
use
proxi
practic
bronchiectasi
children
immunologymicrobiolog
frontier
pediatr
wwwfrontiersinorg
may
volum
articl
organ
respons
exacerb
rare
identifi
physician
gener
reli
empir
evid
treat
respiratori
exacerb
children
bronchiectasi
contamin
upper
airway
microflora
potenti
problem
lower
airway
specimen
obtain
bacteri
cultur
despit
care
techniqu
contamin
may
occur
bal
collect
young
children
tube
use
narrow
protect
brush
method
quantit
cultur
use
exclud
bacteria
present
low
number
bal
fluid
due
upper
airway
contamin
howev
threshold
use
defin
lower
airway
infect
vari
studi
other
use
cutoff
coloni
form
unit
cfu
ml
bal
children
howev
other
use
differ
cutoff
eg
cfuml
adult
studi
cfuml
infant
cystic
fibrosi
although
valid
threshold
cfuml
defin
nthi
lower
airway
infect
use
correl
quantit
pcr
airway
neutrophilia
altern
threshold
bacteri
pathogen
need
investig
identifi
pathogen
respons
lower
airway
infect
complic
limit
laboratori
method
small
proport
bacteria
detect
use
routin
laboratori
cultur
identif
respiratori
pathogen
sputum
bal
alon
prove
causal
infect
improv
cultureindepend
molecular
technolog
show
bronchial
tree
host
divers
microbiota
includ
respiratori
pathogen
peopl
without
respiratori
ill
thu
difficult
distinguish
pathogen
colon
commens
opportunist
colon
individu
patient
nevertheless
member
phylum
proteobacteria
includ
haemophilu
moraxella
spp
strongli
associ
airway
diseas
copd
asthma
adult
children
concept
dysbiosi
microbi
imbal
intestin
flora
long
histori
associ
literatur
huge
contrast
healthi
lung
long
consid
steril
character
healthi
lung
microbiom
rel
recent
develop
studi
use
rrna
gene
sequenc
found
bacteri
commun
healthi
lung
overlap
found
mouth
lower
concentr
np
sampl
show
differ
composit
bacteroidet
particularli
prevotella
spp
frequent
found
mouth
lung
healthi
adult
children
recent
studi
use
rrna
gene
sequenc
found
microbiota
bal
specimen
young
children
chronic
lung
diseas
bronchiectasi
includ
taxa
present
np
op
specimen
divers
use
simpson
index
significantli
lower
np
swab
compar
op
bal
specimen
reflect
common
domin
individu
oper
taxonom
unit
otu
np
microbiota
domin
otu
rel
abund
np
bal
specimen
includ
catarrhali
h
influenza
aureu
miti
group
streptococci
includ
pneumonia
porphyromona
sp
domin
op
specimen
data
support
hypothesi
dynam
bacteri
popul
nasopharynx
primarili
respons
dysbiosi
lung
children
bronchiectasi
although
op
np
analysi
includ
studi
lower
airway
virus
data
avail
character
role
viral
infect
pathogenesi
bronchiectasi
children
howev
recent
data
two
separ
prospect
australian
studi
children
bronchiectasi
indic
attent
virus
warrant
respiratori
virus
associ
exacerb
queensland
children
bronchiectasi
detect
bal
clinic
stabl
children
primarili
indigen
northern
territori
furthermor
studi
bronchiectasi
adult
guangdong
china
respiratori
virus
detect
exacerb
two
pediatr
studi
rhinoviru
commonli
detect
viru
coronaviru
follow
rhinoviru
influenza
common
adult
studi
whether
differ
viral
domin
demograph
driven
associ
diseas
sever
unknown
howev
children
adult
presenc
viru
respiratori
exacerb
associ
sever
symptom
respiratori
virus
import
caus
exacerb
chronic
respiratori
ill
includ
asthma
copd
postul
virus
may
alter
immun
respons
promot
respiratori
exacerb
bacteri
infect
furthermor
bacteriaviru
coinfect
reportedli
result
sever
symptom
australian
indigen
children
carri
high
burden
respiratori
bacteria
young
age
increas
nasopharyng
nthi
densiti
shown
presenc
one
sever
respiratori
virus
indigen
children
acut
om
commonli
detect
virus
rhinoviru
polyomaviru
adenoviru
adenoviru
also
associ
suppur
lung
condit
children
particularli
respect
bacteri
coinfect
respiratori
virus
like
underrecogn
factor
contribut
acut
exacerb
persist
airway
inflamm
children
bronchiectasi
larg
populationbas
pediatr
studi
investig
effect
virus
airway
immunopatholog
import
fulli
appreci
contribut
virus
chronic
inflamm
pathogenesi
bronchiectasi
children
antibiot
therapi
form
cornerston
bronchiectasi
manag
children
antibiot
prescrib
reduc
symptom
prevent
exacerb
preserv
lung
function
reduc
lower
airway
bacteri
load
inflamm
amoxicillin
remain
antibiot
choic
acut
respiratori
infect
due
long
histori
clinic
success
accept
bronchiectasi
children
immunologymicrobiolog
frontier
pediatr
wwwfrontiersinorg
may
volum
articl
limit
side
effect
rel
low
cost
high
dose
amoxicillin
prescrib
penicillinresist
pneumococci
clinic
failur
may
indic
anoth
infect
pathogen
produc
mode
resist
overcom
antibiot
contain
inhibitor
clavulan
acid
oral
amoxicillinclavulan
usual
prescrib
initi
empir
therapi
children
bronchiectasi
mildtomoder
exacerb
macrolid
antibiot
azithromycin
often
use
long
term
manag
bronchiectasi
children
adult
azithromycin
requir
refriger
taken
oral
week
therefor
easili
manag
resourc
poor
set
azithromycin
use
pediatr
patient
sinc
found
safe
welltoler
singledos
regimen
well
convent
regimen
macrolid
activ
pneumonia
h
influenza
catarrhali
aureu
bactericid
effect
p
aeruginosa
inhibit
biofilm
format
macrolid
immunomodulatori
properti
antibacteri
effect
decreas
inflamm
inhibit
bronchial
hyperrespons
improv
mucu
clearanc
may
therefor
play
import
role
manag
bronchiectasi
three
review
mainten
macrolid
therapi
month
durat
bronchiectasi
report
six
rct
adult
four
children
macrolid
therapi
associ
reduc
frequenc
exacerb
adult
risk
ratio
rr
p
children
rr
p
often
improv
pulmonari
function
reduc
sputum
volum
one
rct
lowdos
erythromycin
versu
placebo
children
hivrel
bronchiectasi
found
differ
frequenc
exacerb
increas
macrolid
resist
np
bacteria
pneumonia
aureu
found
rct
children
detail
microbiolog
outcom
howev
adher
medic
australian
azithromycin
group
significantli
associ
lower
carriag
pathogen
fewer
macrolideresist
pathogen
new
zealand
children
took
weekli
dose
directli
observ
therapi
practic
better
adher
treatment
optim
clinic
benefit
also
lower
bacteri
load
minim
prolong
period
submic
antibiot
concentr
may
also
reduc
risk
macrolid
resist
import
implic
physician
consid
longterm
macrolid
antibiot
children
bronchiectasi
sinc
adher
signific
risk
factor
macrolid
resist
current
commerci
avail
vaccin
specif
target
nthi
main
bacteri
pathogen
pediatr
bronchiectasi
oral
vaccin
infect
nthi
success
reduc
number
sever
exacerb
well
carriag
adult
copd
chronic
bronchiti
howev
systemat
review
found
benefit
small
advoc
widespread
nthi
oral
vaccin
peopl
copd
effect
oral
vaccin
may
improv
mucos
protect
reduc
incid
andor
sever
respiratori
infect
caus
nthi
pneumococc
polysaccharid
vaccin
develop
prevent
pneumonia
caus
pneumonia
includ
serotyp
caus
invas
pneumococc
diseas
ipd
polysaccharid
vaccin
introduc
still
use
today
howev
antibodi
respons
immun
polysaccharid
satisfactori
peopl
age
two
respons
less
satisfactori
month
year
age
poor
children
old
conjug
pneumococc
polysaccharid
carrier
protein
improv
immun
respons
among
infant
first
licens
pneumococc
conjug
vaccin
introduc
contain
seven
serotyp
caus
ipd
children
year
old
usa
vaccin
includ
serotyp
subsequ
produc
includ
pneumococc
nthi
protein
conjug
vaccin
phidcv
licens
pcv
effect
reduc
incid
ipd
caus
vaccin
serotyp
howev
pcv
less
effect
reduc
pneumonia
risk
factor
bronchiectasi
reduct
radiolog
confirm
like
bacteri
pneumonia
describ
popul
reduct
other
limit
impact
pneumonia
incid
may
due
rel
contribut
vaccinetyp
pneumococci
set
multipl
pathogen
includ
pneumococc
serotyp
vaccin
preval
publish
clinic
trial
assess
impact
pcv
children
bronchiectasi
although
vaccin
current
recommend
clinic
trial
phidcv
children
protract
bacteri
bronchiti
chronic
suppur
lung
diseas
bronchiectasi
collect
refer
chronic
endobronchi
disord
respiratori
exacerb
primari
outcom
current
underway
recent
found
carriag
serotyp
pneumonia
mostli
nonvaccin
type
pcvvaccin
popul
similar
propens
caus
lower
airway
infect
australian
children
chronic
endobronchi
disord
data
may
argu
pcv
littl
impact
lower
respiratori
infect
popul
howev
phidcv
may
effect
mucos
infect
nthi
await
full
find
clinic
trial
molecular
studi
requir
sinc
h
influenza
strain
hpd
gene
encod
haemophilu
protein
implic
h
influenza
identif
gene
target
use
also
import
implic
vaccin
target
studi
need
determin
preval
hpd
neg
strain
differ
popul
differ
site
carriag
infect
investig
potenti
nthi
vaccin
antigen
vaccin
target
three
main
bacteri
pathogen
pediatr
bronchiectasi
catarrhali
p
aeruginosa
aureu
yet
commerci
avail
develop
review
other
inhal
antiinflammatori
may
strategi
manag
intens
persist
airway
inflamm
associ
bronchiectasi
inhal
nonsteroid
antiinflammatori
nsaid
corticosteroid
propos
potenti
agent
manag
bronchiectasi
howev
two
recent
systemat
review
random
control
clinic
trial
found
evid
support
use
inhal
nsaid
corticosteroid
children
bronchiectasi
review
emphas
gap
knowledg
regard
novel
therapeut
address
airway
inflamm
children
bronchiectasi
need
clear
data
regard
effect
inhal
antiinflammatori
airway
inflamm
longterm
effect
antiinflammatori
recurr
infect
children
bronchiectasi
prior
introduc
therapeut
regim
past
decad
seen
tremend
advanc
understand
immunolog
paramet
associ
bronchiectasi
bronchiectasi
complex
condit
involv
suboptim
adapt
immun
respons
dysregul
inflammatori
respons
culmin
recurr
persist
infect
howev
current
manag
strategi
children
continu
reli
primarili
antibiot
therapi
treatment
prevent
acut
bacteri
infect
physiotherapi
airway
clearanc
strategi
import
novel
multidirect
approach
requir
address
impair
adapt
immun
respons
dysregul
inflammatori
mechan
respons
chronic
inflamm
persist
infect
novel
plausibl
therapeut
direct
may
includ
target
airway
inflamm
use
inhal
antiinflammatori
improv
adapt
immun
respons
pathogen
import
pathogenesi
bronchiectasi
howev
approach
requir
commit
understand
complex
immunolog
associ
suboptim
immun
respons
protect
immun
pathway
prior
develop
incorpor
immunomodul
therapeut
manag
bronchiectasi
children
understand
mechan
drive
immunopatholog
bronchiectasi
potenti
revolution
therapeut
manag
strategi
children
consid
futur
research
endeavor
advanc
manag
prevent
bronchiectasi
children
rapid
advanc
therapeut
persist
inflamm
hinder
difficulti
monitor
effect
airway
inflamm
obtain
lower
airway
specimen
children
challeng
young
children
find
difficult
expector
least
year
age
bronchoscopi
lavag
invas
procedur
perform
anesthesia
noninvas
approach
monitor
inflamm
lung
includ
resolut
inflamm
requir
approach
warrant
investig
includ
use
exhal
breath
condens
biomark
upper
airway
mucos
secret
blood
reflect
lower
airway
inflammatori
process
dysregul
airway
inflamm
appear
link
function
phenotyp
adapt
immun
respons
howev
direct
associ
caus
effect
unknown
like
complex
question
remain
regard
transit
acut
chronic
respons
inappropri
tcell
respons
may
increas
suscept
infect
nthi
prolong
inflamm
due
ineffect
clearanc
mechan
dysregul
pathway
lung
may
promot
environ
support
polar
respons
increas
suscept
infect
nthi
virus
also
plausibl
chronic
inflamm
may
contribut
impair
macrophag
activ
tcell
respons
result
environ
immun
toler
exhaust
understand
immunolog
mechan
behind
chronic
symptom
bronchiectasi
greatli
inform
target
manag
practic
limit
data
suggest
may
possibl
improv
immun
nthi
children
bronchiectasi
vaccin
pcv
contain
singlenthi
antigen
associ
higher
nthidriven
respons
appear
strong
respons
import
immun
nthi
specif
cytokin
profil
correl
protect
unknown
inde
level
produc
children
bronchiectasi
receiv
vaccin
approach
level
obtain
healthi
control
children
children
bronchiectasi
also
produc
higher
level
cytokin
suggest
gener
mix
respons
mix
respons
associ
suboptim
protect
pertussi
effect
vaccin
develop
reli
understand
function
cellmedi
phenotyp
best
correl
protect
infect
nthi
nontyp
haemophilu
influenza
common
known
pathogen
identifi
lower
airway
children
bronchiectasi
howev
respiratori
pathogen
includ
virus
also
common
furthermor
accumul
data
indic
airway
host
divers
microbiota
includ
respiratori
pathogen
peopl
without
respiratori
diseas
thu
distinguish
infect
opportunist
colon
difficult
propos
literatur
respiratori
diseas
may
better
character
chang
phenotyp
profil
microbiota
detail
data
investig
rel
effect
chang
lung
microbiota
immun
function
children
lack
studi
would
provid
import
inform
regard
immun
develop
pathogenesi
bronchiectasi
bacteri
load
threshold
defin
lower
airway
infect
respiratori
societi
introduc
guidelin
collect
bal
fluid
microbiolog
immunolog
analysi
howev
instrument
techniqu
sampl
prepar
vari
wide
center
individu
oper
effect
phenotyp
qualiti
sampl
must
consid
report
result
although
valid
threshold
cfuml
defin
nthi
lower
airway
infect
set
altern
threshold
investig
multipl
biolog
clinic
marker
consist
disrupt
airway
homeostasi
consid
develop
algorithm
defin
threshold
infect
associ
bacteri
load
inflammatori
marker
may
differ
bacteri
speci
welldefin
threshold
infect
account
oper
variabl
import
understand
contribut
pathogen
lower
airway
inflamm
children
bronchiectasi
whole
genom
sequenc
wg
need
understand
virul
antibiot
resist
determin
import
bacteri
pathogen
report
higher
rate
resist
bal
compar
np
isol
nthi
pneumonia
catarrhali
lower
airway
strain
may
harbor
significantli
higher
proport
genet
variant
favor
persist
confer
antimicrobi
resist
compar
np
strain
children
andor
asymptomat
carrier
wg
studi
need
determin
preval
hpdneg
nthi
strain
differ
popul
differ
site
carriag
infect
investig
potenti
vaccin
antigen
nthi
pathogen
inform
may
prove
valuabl
develop
vaccin
therapeut
agent
suboptim
adapt
immun
respons
addit
dysregul
local
inflammatori
respons
like
contribut
environ
conduc
chronic
recurr
infect
effect
manag
strategi
bronchiectasi
children
requir
understand
advers
immunolog
event
lead
recurr
infect
persist
inflamm
promot
environ
support
effici
pathogen
clearanc
rapid
resolut
inflammatori
respons
forefront
futur
endeavor
combat
condit
larg
prevent
sp
kh
ju
wrote
edit
review
work
support
nation
health
medic
research
council
australia
earli
career
fellowship
sp
kh
project
grant
ju
